nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—P-Glycoprotein Inhibitors—Cyclosporine—focal segmental glomerulosclerosis	0.812	1	CiPCiCtD
Bosutinib—Upper gastrointestinal haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.0048	0.205	CcSEcCtD
Bosutinib—Traumatic liver injury—Cyclosporine—focal segmental glomerulosclerosis	0.00148	0.0633	CcSEcCtD
Bosutinib—Pancreatitis acute—Cyclosporine—focal segmental glomerulosclerosis	0.0012	0.0511	CcSEcCtD
Bosutinib—PTK2—endothelium—focal segmental glomerulosclerosis	0.00113	0.0196	CbGeAlD
Bosutinib—EPHB4—endothelium—focal segmental glomerulosclerosis	0.00103	0.0178	CbGeAlD
Bosutinib—VRK2—nephron tubule—focal segmental glomerulosclerosis	0.000938	0.0163	CbGeAlD
Bosutinib—TLK1—cortex of kidney—focal segmental glomerulosclerosis	0.000926	0.0161	CbGeAlD
Bosutinib—PRKCQ—cortex of kidney—focal segmental glomerulosclerosis	0.000913	0.0158	CbGeAlD
Bosutinib—STK26—nephron tubule—focal segmental glomerulosclerosis	0.000903	0.0157	CbGeAlD
Bosutinib—SRC—endothelium—focal segmental glomerulosclerosis	0.000874	0.0152	CbGeAlD
Bosutinib—WEE1—nephron tubule—focal segmental glomerulosclerosis	0.000865	0.015	CbGeAlD
Bosutinib—DSTYK—cortex of kidney—focal segmental glomerulosclerosis	0.000857	0.0149	CbGeAlD
Bosutinib—CLK3—cortex of kidney—focal segmental glomerulosclerosis	0.000857	0.0149	CbGeAlD
Bosutinib—SRMS—kidney—focal segmental glomerulosclerosis	0.000841	0.0146	CbGeAlD
Bosutinib—EIF2AK1—cortex of kidney—focal segmental glomerulosclerosis	0.000828	0.0144	CbGeAlD
Bosutinib—STK25—nephron tubule—focal segmental glomerulosclerosis	0.000826	0.0143	CbGeAlD
Bosutinib—SYK—kidney—focal segmental glomerulosclerosis	0.000808	0.014	CbGeAlD
Bosutinib—VRK2—cortex of kidney—focal segmental glomerulosclerosis	0.000803	0.0139	CbGeAlD
Bosutinib—CDK2—kidney—focal segmental glomerulosclerosis	0.000801	0.0139	CbGeAlD
Bosutinib—SIK3—nephron tubule—focal segmental glomerulosclerosis	0.000798	0.0138	CbGeAlD
Bosutinib—STK26—kidney—focal segmental glomerulosclerosis	0.000793	0.0138	CbGeAlD
Bosutinib—SYK—cortex of kidney—focal segmental glomerulosclerosis	0.000787	0.0136	CbGeAlD
Bosutinib—STK26—cortex of kidney—focal segmental glomerulosclerosis	0.000773	0.0134	CbGeAlD
Bosutinib—DMPK—cortex of kidney—focal segmental glomerulosclerosis	0.00074	0.0128	CbGeAlD
Bosutinib—WEE1—cortex of kidney—focal segmental glomerulosclerosis	0.00074	0.0128	CbGeAlD
Bosutinib—Hepatotoxicity—Cyclosporine—focal segmental glomerulosclerosis	0.000716	0.0306	CcSEcCtD
Bosutinib—STK25—cortex of kidney—focal segmental glomerulosclerosis	0.000707	0.0123	CbGeAlD
Bosutinib—PLK2—kidney—focal segmental glomerulosclerosis	0.000706	0.0122	CbGeAlD
Bosutinib—PLK2—cortex of kidney—focal segmental glomerulosclerosis	0.000687	0.0119	CbGeAlD
Bosutinib—SIK3—cortex of kidney—focal segmental glomerulosclerosis	0.000683	0.0118	CbGeAlD
Bosutinib—Liver injury—Cyclosporine—focal segmental glomerulosclerosis	0.000657	0.028	CcSEcCtD
Bosutinib—Acne—Cyclosporine—focal segmental glomerulosclerosis	0.000657	0.028	CcSEcCtD
Bosutinib—STK24—cortex of kidney—focal segmental glomerulosclerosis	0.000642	0.0111	CbGeAlD
Bosutinib—MAP4K4—nephron tubule—focal segmental glomerulosclerosis	0.000626	0.0109	CbGeAlD
Bosutinib—NUAK2—nephron tubule—focal segmental glomerulosclerosis	0.000621	0.0108	CbGeAlD
Bosutinib—BCR—nephron tubule—focal segmental glomerulosclerosis	0.000621	0.0108	CbGeAlD
Bosutinib—FER—cortex of kidney—focal segmental glomerulosclerosis	0.000621	0.0108	CbGeAlD
Bosutinib—CSK—nephron tubule—focal segmental glomerulosclerosis	0.0006	0.0104	CbGeAlD
Bosutinib—CSNK1A1—nephron tubule—focal segmental glomerulosclerosis	0.000597	0.0103	CbGeAlD
Bosutinib—CLK1—nephron tubule—focal segmental glomerulosclerosis	0.000593	0.0103	CbGeAlD
Bosutinib—ROCK1—kidney—focal segmental glomerulosclerosis	0.000588	0.0102	CbGeAlD
Bosutinib—ERBB4—cortex of kidney—focal segmental glomerulosclerosis	0.00058	0.0101	CbGeAlD
Bosutinib—STK3—cortex of kidney—focal segmental glomerulosclerosis	0.00058	0.0101	CbGeAlD
Bosutinib—BMPR2—kidney—focal segmental glomerulosclerosis	0.000571	0.00991	CbGeAlD
Bosutinib—BMPR2—cortex of kidney—focal segmental glomerulosclerosis	0.000556	0.00965	CbGeAlD
Bosutinib—STK36—cortex of kidney—focal segmental glomerulosclerosis	0.000552	0.00957	CbGeAlD
Bosutinib—MAP4K4—kidney—focal segmental glomerulosclerosis	0.00055	0.00954	CbGeAlD
Bosutinib—SIK1—nephron tubule—focal segmental glomerulosclerosis	0.000544	0.00944	CbGeAlD
Bosutinib—Hyperkalaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000543	0.0232	CcSEcCtD
Bosutinib—ERBB3—nephron tubule—focal segmental glomerulosclerosis	0.000533	0.00925	CbGeAlD
Bosutinib—NUAK2—cortex of kidney—focal segmental glomerulosclerosis	0.000532	0.00922	CbGeAlD
Bosutinib—BCR—cortex of kidney—focal segmental glomerulosclerosis	0.000532	0.00922	CbGeAlD
Bosutinib—MAP2K1—kidney—focal segmental glomerulosclerosis	0.000531	0.00921	CbGeAlD
Bosutinib—MAP3K2—nephron tubule—focal segmental glomerulosclerosis	0.000528	0.00916	CbGeAlD
Bosutinib—CSK—kidney—focal segmental glomerulosclerosis	0.000528	0.00915	CbGeAlD
Bosutinib—Fluid retention—Cyclosporine—focal segmental glomerulosclerosis	0.000525	0.0224	CcSEcCtD
Bosutinib—CSNK1A1—kidney—focal segmental glomerulosclerosis	0.000524	0.00909	CbGeAlD
Bosutinib—CLK1—kidney—focal segmental glomerulosclerosis	0.000521	0.00903	CbGeAlD
Bosutinib—TBK1—nephron tubule—focal segmental glomerulosclerosis	0.000517	0.00897	CbGeAlD
Bosutinib—PTK2—nephron tubule—focal segmental glomerulosclerosis	0.000517	0.00897	CbGeAlD
Bosutinib—CSK—cortex of kidney—focal segmental glomerulosclerosis	0.000514	0.00891	CbGeAlD
Bosutinib—CSNK1A1—cortex of kidney—focal segmental glomerulosclerosis	0.000511	0.00885	CbGeAlD
Bosutinib—CLK1—cortex of kidney—focal segmental glomerulosclerosis	0.000507	0.0088	CbGeAlD
Bosutinib—IRAK1—nephron tubule—focal segmental glomerulosclerosis	0.000507	0.00879	CbGeAlD
Bosutinib—LRRK2—kidney—focal segmental glomerulosclerosis	0.000507	0.00879	CbGeAlD
Bosutinib—CAMK2G—cortex of kidney—focal segmental glomerulosclerosis	0.000498	0.00863	CbGeAlD
Bosutinib—PTK2B—kidney—focal segmental glomerulosclerosis	0.000494	0.00856	CbGeAlD
Bosutinib—LRRK2—cortex of kidney—focal segmental glomerulosclerosis	0.000493	0.00856	CbGeAlD
Bosutinib—SIK1—kidney—focal segmental glomerulosclerosis	0.000478	0.00829	CbGeAlD
Bosutinib—SLK—nephron tubule—focal segmental glomerulosclerosis	0.000474	0.00822	CbGeAlD
Bosutinib—CSNK1E—cortex of kidney—focal segmental glomerulosclerosis	0.000473	0.0082	CbGeAlD
Bosutinib—EPHB4—nephron tubule—focal segmental glomerulosclerosis	0.000471	0.00816	CbGeAlD
Bosutinib—ERBB3—kidney—focal segmental glomerulosclerosis	0.000469	0.00813	CbGeAlD
Bosutinib—MAP2K2—kidney—focal segmental glomerulosclerosis	0.000468	0.00811	CbGeAlD
Bosutinib—SIK1—cortex of kidney—focal segmental glomerulosclerosis	0.000466	0.00808	CbGeAlD
Bosutinib—EPHA2—nephron tubule—focal segmental glomerulosclerosis	0.000462	0.00801	CbGeAlD
Bosutinib—FYN—nephron tubule—focal segmental glomerulosclerosis	0.000461	0.008	CbGeAlD
Bosutinib—Hepatic function abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.000459	0.0196	CcSEcCtD
Bosutinib—MAP2K2—cortex of kidney—focal segmental glomerulosclerosis	0.000455	0.0079	CbGeAlD
Bosutinib—ULK3—cortex of kidney—focal segmental glomerulosclerosis	0.000455	0.0079	CbGeAlD
Bosutinib—TBK1—kidney—focal segmental glomerulosclerosis	0.000455	0.00788	CbGeAlD
Bosutinib—PTK2—kidney—focal segmental glomerulosclerosis	0.000455	0.00788	CbGeAlD
Bosutinib—MAP3K3—nephron tubule—focal segmental glomerulosclerosis	0.000451	0.00781	CbGeAlD
Bosutinib—MAP3K7—cortex of kidney—focal segmental glomerulosclerosis	0.000448	0.00777	CbGeAlD
Bosutinib—PTK2—cortex of kidney—focal segmental glomerulosclerosis	0.000443	0.00768	CbGeAlD
Bosutinib—TBK1—cortex of kidney—focal segmental glomerulosclerosis	0.000443	0.00768	CbGeAlD
Bosutinib—RPS6KB1—kidney—focal segmental glomerulosclerosis	0.000437	0.00758	CbGeAlD
Bosutinib—IRAK1—cortex of kidney—focal segmental glomerulosclerosis	0.000434	0.00753	CbGeAlD
Bosutinib—RPS6KB1—cortex of kidney—focal segmental glomerulosclerosis	0.000426	0.00739	CbGeAlD
Bosutinib—AXL—cortex of kidney—focal segmental glomerulosclerosis	0.000422	0.00731	CbGeAlD
Bosutinib—Renal impairment—Cyclosporine—focal segmental glomerulosclerosis	0.000422	0.018	CcSEcCtD
Bosutinib—YES1—nephron tubule—focal segmental glomerulosclerosis	0.000416	0.00722	CbGeAlD
Bosutinib—EPHB4—kidney—focal segmental glomerulosclerosis	0.000414	0.00717	CbGeAlD
Bosutinib—TAOK3—nephron tubule—focal segmental glomerulosclerosis	0.000411	0.00712	CbGeAlD
Bosutinib—SLK—cortex of kidney—focal segmental glomerulosclerosis	0.000406	0.00704	CbGeAlD
Bosutinib—FYN—kidney—focal segmental glomerulosclerosis	0.000405	0.00703	CbGeAlD
Bosutinib—EPHB4—cortex of kidney—focal segmental glomerulosclerosis	0.000403	0.00699	CbGeAlD
Bosutinib—FYN—cortex of kidney—focal segmental glomerulosclerosis	0.000395	0.00684	CbGeAlD
Bosutinib—MAP3K3—cortex of kidney—focal segmental glomerulosclerosis	0.000386	0.00669	CbGeAlD
Bosutinib—MAP4K5—cortex of kidney—focal segmental glomerulosclerosis	0.000386	0.00669	CbGeAlD
Bosutinib—Blood creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.000376	0.016	CcSEcCtD
Bosutinib—Abdominal pain upper—Cyclosporine—focal segmental glomerulosclerosis	0.000367	0.0156	CcSEcCtD
Bosutinib—YES1—kidney—focal segmental glomerulosclerosis	0.000366	0.00634	CbGeAlD
Bosutinib—STK10—kidney—focal segmental glomerulosclerosis	0.000362	0.00628	CbGeAlD
Bosutinib—TAOK3—kidney—focal segmental glomerulosclerosis	0.000361	0.00626	CbGeAlD
Bosutinib—YES1—cortex of kidney—focal segmental glomerulosclerosis	0.000356	0.00618	CbGeAlD
Bosutinib—Gastritis—Cyclosporine—focal segmental glomerulosclerosis	0.000355	0.0152	CcSEcCtD
Bosutinib—SRC—kidney—focal segmental glomerulosclerosis	0.000352	0.0061	CbGeAlD
Bosutinib—TAOK3—cortex of kidney—focal segmental glomerulosclerosis	0.000352	0.0061	CbGeAlD
Bosutinib—Bronchitis—Cyclosporine—focal segmental glomerulosclerosis	0.000334	0.0142	CcSEcCtD
Bosutinib—Abdominal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000333	0.0142	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.000322	0.0138	CcSEcCtD
Bosutinib—MAP2K5—cortex of kidney—focal segmental glomerulosclerosis	0.000315	0.00547	CbGeAlD
Bosutinib—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.000311	0.0133	CcSEcCtD
Bosutinib—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.000309	0.0132	CcSEcCtD
Bosutinib—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.000309	0.0132	CcSEcCtD
Bosutinib—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.000304	0.013	CcSEcCtD
Bosutinib—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.000292	0.0125	CcSEcCtD
Bosutinib—ABL1—nephron tubule—focal segmental glomerulosclerosis	0.000284	0.00493	CbGeAlD
Bosutinib—PDGFRB—kidney—focal segmental glomerulosclerosis	0.00028	0.00486	CbGeAlD
Bosutinib—Hepatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000278	0.0118	CcSEcCtD
Bosutinib—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000274	0.0117	CcSEcCtD
Bosutinib—PDGFRB—cortex of kidney—focal segmental glomerulosclerosis	0.000273	0.00473	CbGeAlD
Bosutinib—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000273	0.0116	CcSEcCtD
Bosutinib—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000272	0.0116	CcSEcCtD
Bosutinib—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.000259	0.011	CcSEcCtD
Bosutinib—Vandetanib—ALB—focal segmental glomerulosclerosis	0.000258	0.513	CrCbGaD
Bosutinib—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00025	0.0107	CcSEcCtD
Bosutinib—ABL1—kidney—focal segmental glomerulosclerosis	0.00025	0.00433	CbGeAlD
Bosutinib—Gefitinib—ALB—focal segmental glomerulosclerosis	0.000246	0.487	CrCbGaD
Bosutinib—ABL1—cortex of kidney—focal segmental glomerulosclerosis	0.000243	0.00422	CbGeAlD
Bosutinib—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.000242	0.0103	CcSEcCtD
Bosutinib—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.000237	0.0101	CcSEcCtD
Bosutinib—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000224	0.00957	CcSEcCtD
Bosutinib—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000223	0.00953	CcSEcCtD
Bosutinib—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.000218	0.0093	CcSEcCtD
Bosutinib—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000216	0.00923	CcSEcCtD
Bosutinib—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.000211	0.009	CcSEcCtD
Bosutinib—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.000206	0.00878	CcSEcCtD
Bosutinib—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.000206	0.00878	CcSEcCtD
Bosutinib—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.000206	0.00878	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.000204	0.00872	CcSEcCtD
Bosutinib—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000203	0.00868	CcSEcCtD
Bosutinib—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.000197	0.00842	CcSEcCtD
Bosutinib—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.000197	0.00842	CcSEcCtD
Bosutinib—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.000196	0.00836	CcSEcCtD
Bosutinib—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000193	0.00826	CcSEcCtD
Bosutinib—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000193	0.00824	CcSEcCtD
Bosutinib—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000192	0.00818	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00018	0.00767	CcSEcCtD
Bosutinib—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.000176	0.00751	CcSEcCtD
Bosutinib—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.000171	0.00732	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00017	0.00727	CcSEcCtD
Bosutinib—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.00017	0.00726	CcSEcCtD
Bosutinib—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.000169	0.0072	CcSEcCtD
Bosutinib—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.000163	0.00694	CcSEcCtD
Bosutinib—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000161	0.00688	CcSEcCtD
Bosutinib—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.000157	0.00669	CcSEcCtD
Bosutinib—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.000156	0.00665	CcSEcCtD
Bosutinib—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000156	0.00665	CcSEcCtD
Bosutinib—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.000142	0.00604	CcSEcCtD
Bosutinib—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.00014	0.00596	CcSEcCtD
Bosutinib—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000135	0.00576	CcSEcCtD
Bosutinib—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.00013	0.00557	CcSEcCtD
Bosutinib—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000125	0.00535	CcSEcCtD
Bosutinib—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.000124	0.00531	CcSEcCtD
Bosutinib—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000124	0.0053	CcSEcCtD
Bosutinib—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.000124	0.00527	CcSEcCtD
Bosutinib—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.000117	0.005	CcSEcCtD
Bosutinib—CYP3A4—kidney—focal segmental glomerulosclerosis	0.00011	0.0019	CbGeAlD
Bosutinib—ABCB1—nephron tubule—focal segmental glomerulosclerosis	8.83e-05	0.00153	CbGeAlD
Bosutinib—ABCB1—kidney—focal segmental glomerulosclerosis	7.76e-05	0.00135	CbGeAlD
Bosutinib—ABCB1—cortex of kidney—focal segmental glomerulosclerosis	7.56e-05	0.00131	CbGeAlD
Bosutinib—AXL—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	3.66e-06	3.42e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—CD40LG—focal segmental glomerulosclerosis	3.65e-06	3.42e-05	CbGpPWpGaD
Bosutinib—SRC—Axon guidance—MMP9—focal segmental glomerulosclerosis	3.65e-06	3.41e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—LPL—focal segmental glomerulosclerosis	3.62e-06	3.38e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	3.59e-06	3.36e-05	CbGpPWpGaD
Bosutinib—LYN—Developmental Biology—MMP9—focal segmental glomerulosclerosis	3.58e-06	3.35e-05	CbGpPWpGaD
Bosutinib—ABL1—Developmental Biology—MMP9—focal segmental glomerulosclerosis	3.57e-06	3.34e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	3.55e-06	3.32e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	3.55e-06	3.32e-05	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	3.55e-06	3.32e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—LPL—focal segmental glomerulosclerosis	3.54e-06	3.31e-05	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—MMP9—focal segmental glomerulosclerosis	3.53e-06	3.3e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	3.51e-06	3.29e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—MMP9—focal segmental glomerulosclerosis	3.51e-06	3.28e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—AGT—focal segmental glomerulosclerosis	3.51e-06	3.28e-05	CbGpPWpGaD
Bosutinib—BMPR2—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	3.49e-06	3.26e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Disease—TGFB1—focal segmental glomerulosclerosis	3.48e-06	3.26e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Disease—TGFB1—focal segmental glomerulosclerosis	3.48e-06	3.26e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—MMP2—focal segmental glomerulosclerosis	3.46e-06	3.24e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—AGT—focal segmental glomerulosclerosis	3.46e-06	3.24e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—LPL—focal segmental glomerulosclerosis	3.45e-06	3.23e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	3.45e-06	3.22e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	3.42e-06	3.2e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—SERPINE1—focal segmental glomerulosclerosis	3.4e-06	3.18e-05	CbGpPWpGaD
Bosutinib—CSK—Disease—TGFB1—focal segmental glomerulosclerosis	3.36e-06	3.15e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	3.36e-06	3.14e-05	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	3.34e-06	3.13e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	3.33e-06	3.12e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	3.33e-06	3.12e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—LPL—focal segmental glomerulosclerosis	3.33e-06	3.11e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—ALB—focal segmental glomerulosclerosis	3.33e-06	3.11e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—CD79A—focal segmental glomerulosclerosis	3.32e-06	3.11e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	3.32e-06	3.1e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—LPL—focal segmental glomerulosclerosis	3.31e-06	3.1e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	3.29e-06	3.08e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	3.27e-06	3.06e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—FN1—focal segmental glomerulosclerosis	3.24e-06	3.03e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—LPL—focal segmental glomerulosclerosis	3.22e-06	3.01e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	3.21e-06	3.01e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	3.21e-06	3e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—AGT—focal segmental glomerulosclerosis	3.21e-06	3e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	3.2e-06	2.99e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—FN1—focal segmental glomerulosclerosis	3.19e-06	2.99e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	3.18e-06	2.98e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	3.17e-06	2.97e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—CD40LG—focal segmental glomerulosclerosis	3.17e-06	2.97e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	3.15e-06	2.94e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	3.12e-06	2.92e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	3.1e-06	2.9e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	3.1e-06	2.9e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—AGT—focal segmental glomerulosclerosis	3.09e-06	2.89e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	3.09e-06	2.89e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	3.08e-06	2.89e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	3.08e-06	2.88e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	3.08e-06	2.88e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	3.07e-06	2.87e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—CD40LG—focal segmental glomerulosclerosis	3.06e-06	2.86e-05	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—MMP9—focal segmental glomerulosclerosis	3.05e-06	2.85e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	3.05e-06	2.85e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	3.01e-06	2.82e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	3.01e-06	2.82e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	3.01e-06	2.82e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	3.01e-06	2.81e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.96e-06	2.77e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.96e-06	2.77e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.96e-06	2.77e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.96e-06	2.77e-05	CbGpPWpGaD
Bosutinib—LYN—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	2.95e-06	2.76e-05	CbGpPWpGaD
Bosutinib—ABL1—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	2.94e-06	2.75e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.94e-06	2.75e-05	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.92e-06	2.73e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.92e-06	2.73e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	2.91e-06	2.73e-05	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	2.91e-06	2.72e-05	CbGpPWpGaD
Bosutinib—LYN—Hemostasis—TGFB1—focal segmental glomerulosclerosis	2.9e-06	2.71e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	2.89e-06	2.71e-05	CbGpPWpGaD
Bosutinib—ABL1—Hemostasis—TGFB1—focal segmental glomerulosclerosis	2.88e-06	2.7e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.88e-06	2.69e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—LPL—focal segmental glomerulosclerosis	2.87e-06	2.69e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.86e-06	2.67e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.86e-06	2.67e-05	CbGpPWpGaD
Bosutinib—FYN—Hemostasis—TGFB1—focal segmental glomerulosclerosis	2.85e-06	2.67e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.85e-06	2.67e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.83e-06	2.65e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.83e-06	2.65e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.82e-06	2.64e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Disease—TGFB1—focal segmental glomerulosclerosis	2.81e-06	2.63e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—LPL—focal segmental glomerulosclerosis	2.77e-06	2.59e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—NOS2—focal segmental glomerulosclerosis	2.76e-06	2.59e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.75e-06	2.58e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	2.73e-06	2.56e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.71e-06	2.54e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	2.71e-06	2.54e-05	CbGpPWpGaD
Bosutinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	2.71e-06	2.54e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—CD40LG—focal segmental glomerulosclerosis	2.71e-06	2.53e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.7e-06	2.52e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—NOS2—focal segmental glomerulosclerosis	2.7e-06	2.52e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.68e-06	2.51e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.68e-06	2.5e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.66e-06	2.49e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—MMP9—focal segmental glomerulosclerosis	2.6e-06	2.43e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—NOS2—focal segmental glomerulosclerosis	2.6e-06	2.43e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—NOS2—focal segmental glomerulosclerosis	2.58e-06	2.42e-05	CbGpPWpGaD
Bosutinib—HCK—Disease—TGFB1—focal segmental glomerulosclerosis	2.58e-06	2.42e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.58e-06	2.41e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.57e-06	2.41e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.56e-06	2.4e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.55e-06	2.39e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.54e-06	2.38e-05	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	2.51e-06	2.35e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.51e-06	2.35e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.49e-06	2.33e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.48e-06	2.33e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.48e-06	2.32e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.47e-06	2.31e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.47e-06	2.31e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—LPL—focal segmental glomerulosclerosis	2.45e-06	2.29e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.45e-06	2.29e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.44e-06	2.28e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.44e-06	2.28e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.44e-06	2.28e-05	CbGpPWpGaD
Bosutinib—ERBB4—Disease—TGFB1—focal segmental glomerulosclerosis	2.43e-06	2.28e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.42e-06	2.27e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.42e-06	2.26e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.4e-06	2.25e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.39e-06	2.24e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.39e-06	2.23e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.38e-06	2.23e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.38e-06	2.23e-05	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—TGFB1—focal segmental glomerulosclerosis	2.38e-06	2.22e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.37e-06	2.21e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.36e-06	2.21e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.36e-06	2.2e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.35e-06	2.2e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.33e-06	2.18e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—SERPINE1—focal segmental glomerulosclerosis	2.33e-06	2.18e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.32e-06	2.17e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.29e-06	2.14e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.28e-06	2.14e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—SERPINE1—focal segmental glomerulosclerosis	2.27e-06	2.12e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—NOS2—focal segmental glomerulosclerosis	2.24e-06	2.1e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.24e-06	2.1e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.24e-06	2.1e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.21e-06	2.06e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.19e-06	2.05e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—SERPINE1—focal segmental glomerulosclerosis	2.19e-06	2.05e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—SERPINE1—focal segmental glomerulosclerosis	2.18e-06	2.04e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—NOS2—focal segmental glomerulosclerosis	2.16e-06	2.02e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	2.14e-06	2.01e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—TGFB1—focal segmental glomerulosclerosis	2.14e-06	2.01e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.12e-06	1.98e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.12e-06	1.98e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—TGFB1—focal segmental glomerulosclerosis	2.1e-06	1.97e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.09e-06	1.95e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.09e-06	1.95e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.07e-06	1.94e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.07e-06	1.93e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.07e-06	1.93e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.04e-06	1.91e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.02e-06	1.89e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.01e-06	1.88e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2e-06	1.87e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.99e-06	1.87e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—LIPC—focal segmental glomerulosclerosis	1.99e-06	1.86e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.98e-06	1.86e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.98e-06	1.85e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.97e-06	1.84e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.96e-06	1.84e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.96e-06	1.83e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.94e-06	1.82e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—NOS2—focal segmental glomerulosclerosis	1.92e-06	1.79e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.91e-06	1.79e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.91e-06	1.78e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—SERPINE1—focal segmental glomerulosclerosis	1.89e-06	1.77e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.89e-06	1.77e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.89e-06	1.77e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.87e-06	1.75e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.86e-06	1.74e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.84e-06	1.72e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.84e-06	1.72e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.83e-06	1.71e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—SERPINE1—focal segmental glomerulosclerosis	1.82e-06	1.7e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.82e-06	1.7e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.77e-06	1.66e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CTGF—focal segmental glomerulosclerosis	1.75e-06	1.64e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.72e-06	1.61e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.72e-06	1.61e-05	CbGpPWpGaD
Bosutinib—ABCB1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	1.7e-06	1.59e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.7e-06	1.59e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.68e-06	1.57e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.66e-06	1.55e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.63e-06	1.52e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.63e-06	1.52e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.62e-06	1.52e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.62e-06	1.51e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.61e-06	1.51e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—SERPINE1—focal segmental glomerulosclerosis	1.61e-06	1.51e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.6e-06	1.5e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.59e-06	1.49e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.59e-06	1.49e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.56e-06	1.46e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.56e-06	1.46e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.56e-06	1.46e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.53e-06	1.43e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.53e-06	1.43e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.52e-06	1.43e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.52e-06	1.42e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.5e-06	1.4e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.47e-06	1.37e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—TGFB1—focal segmental glomerulosclerosis	1.47e-06	1.37e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—TGFB1—focal segmental glomerulosclerosis	1.43e-06	1.34e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.43e-06	1.34e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—TGFB1—focal segmental glomerulosclerosis	1.38e-06	1.29e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—TGFB1—focal segmental glomerulosclerosis	1.37e-06	1.29e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.36e-06	1.27e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.34e-06	1.25e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.32e-06	1.24e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.32e-06	1.23e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.28e-06	1.19e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.25e-06	1.17e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.25e-06	1.17e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	1.23e-06	1.15e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.22e-06	1.14e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—LPL—focal segmental glomerulosclerosis	1.21e-06	1.14e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—TGFB1—focal segmental glomerulosclerosis	1.19e-06	1.12e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.19e-06	1.12e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.18e-06	1.1e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.17e-06	1.1e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.17e-06	1.09e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—TGFB1—focal segmental glomerulosclerosis	1.15e-06	1.08e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.13e-06	1.06e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	1.08e-06	1.01e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AGT—focal segmental glomerulosclerosis	1.04e-06	9.73e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.03e-06	9.62e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—TGFB1—focal segmental glomerulosclerosis	1.02e-06	9.53e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.01e-06	9.49e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1e-06	9.39e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	9.95e-07	9.31e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	9.83e-07	9.2e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	9.77e-07	9.14e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	9.67e-07	9.05e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	9.62e-07	9e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	8.65e-07	8.1e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	8.36e-07	7.82e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	8.05e-07	7.54e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ALB—focal segmental glomerulosclerosis	7.98e-07	7.46e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	7.49e-07	7e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	7.13e-07	6.67e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	6.4e-07	5.99e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	4.91e-07	4.6e-06	CbGpPWpGaD
